{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:49:41Z","timestamp":1778906981282,"version":"3.51.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1097\/md.0000000000003341","type":"journal-article","created":{"date-parts":[[2016,5,2]],"date-time":"2016-05-02T18:33:10Z","timestamp":1462213990000},"page":"e3341","source":"Crossref","is-referenced-by-count":11,"title":["The Adverse Events of Oxycodone in Cancer-Related Pain"],"prefix":"10.1097","volume":"95","author":[{"given":"Hu","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Tao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Han","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Jun","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Guo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-51-20210309","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/0269216311401948","article-title":"A systematic review of oxycodone in the management of cancer pain","volume":"25","author":"King","year":"2011","journal-title":"Palliat Med"},{"key":"R2-51-20210309","doi-asserted-by":"crossref","first-page":"E343","DOI":"10.36076\/ppj.2011\/14\/E343","article-title":"Pharmacology of opioids in the treatment of chronic pain syndromes","volume":"14","author":"Vallejo","year":"2011","journal-title":"Pain Physician"},{"key":"R3-51-20210309","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpainsymman.2014.05.021","article-title":"Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial","volume":"49","author":"Riley","year":"2015","journal-title":"J Pain Symptom Manag"},{"key":"R4-51-20210309","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.7314\/APJCP.2014.15.20.8797","article-title":"Pharmacoeconomics evaluation of morphine, MS contin and oxycodone in the treatment of cancer pain","volume":"15","author":"Zhang","year":"2014","journal-title":"Asian Pac J Cancer P"},{"key":"R5-51-20210309","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jpain.2014.04.008","article-title":"Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study","volume":"15","author":"Yu","year":"2014","journal-title":"J Pain"},{"key":"R6-51-20210309","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/0269216311418869","article-title":"A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone\/naloxone prolonged-release tablets in patients with moderate\/severe, chronic cancer pain","volume":"26","author":"Ahmedzai","year":"2011","journal-title":"Palliat Med"},{"key":"R7-51-20210309","first-page":"1983","article-title":"The observation of curative effect of oxycodone hydrochloride controlled-release fablets in management of moderate and severe cancer pain","volume":"16","author":"Wang","year":"2008","journal-title":"Chin Mod Oncol"},{"key":"R8-51-20210309","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1185\/030079904125003854","article-title":"Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study","volume":"20","author":"Gabrail","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"R9-51-20210309","first-page":"16","article-title":"Clinical efficacy of oxycodone hydrochloride controlled-release tablets for cancer pain","volume":"10","author":"Li","year":"2002","journal-title":"Shanxi Oncol Med (China"},{"key":"R10-51-20210309","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1090-3801(98)90020-9","article-title":"Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study","volume":"2","author":"Mucci-LoRusso","year":"1998","journal-title":"Eur J Pain"},{"key":"R11-51-20210309","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/0269216311406313","article-title":"A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project","volume":"25","author":"King","year":"2011","journal-title":"Palliat Med"},{"key":"R12-51-20210309","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3892\/etm.2012.571","article-title":"Efficacy and tolerability of oxycodone in moderate-severe cancer-related pain: a meta-analysis of randomized controlled trials","volume":"4","author":"Wang","year":"2012","journal-title":"Exp Ther Med"},{"key":"R13-51-20210309","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jpainsymman.2014.09.018","article-title":"A systematic review of strategies used to increase recruitment of people with cancer or organ failure into clinical trials: implications for palliative care research","volume":"49","author":"Boland","year":"2015","journal-title":"J Pain Symptom Manage"},{"key":"R14-51-20210309","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jpain.2015.05.006","article-title":"A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures","volume":"16","author":"Oosten","year":"2015","journal-title":"J Pain"},{"key":"R15-51-20210309","first-page":"Cd003870","article-title":"Oxycodone for cancer-related pain","volume":"2","author":"Schmidt-Hansen","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R16-51-20210309","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"R17-51-20210309","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R18-51-20210309","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R19-51-20210309","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R21-51-20210309","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"R22-51-20210309","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R23-51-20210309","doi-asserted-by":"crossref","first-page":"e1719","DOI":"10.1097\/MD.0000000000001719","article-title":"The risk of neutropenia and leukopenia in advanced non-small cell lung cancer patients treated with erlotinib: a PRISMA-compliant systematic review and meta-analysis","volume":"94","author":"Zhou","year":"2015","journal-title":"Medicine (Baltimore"},{"key":"R24-51-20210309","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3758\/BRM.41.1.35","article-title":"A SAS macro for statistical power calculations in meta-analysis","volume":"41","author":"Cafri","year":"2009","journal-title":"Behav Res Methods"},{"key":"R25-51-20210309","first-page":"1277","article-title":"Clinical efficacy of oxycodone hydrochloride controlled-release tablets in management of moderate and severe cancer pain","volume":"27","author":"Yu","year":"2007","journal-title":"Chin J Hosp Pharm"},{"key":"R26-51-20210309","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0304-3959(97)00072-9","article-title":"Controlled-release oxycodone and morphine in cancer related pain","volume":"73","author":"Heiskanen","year":"1997","journal-title":"Pain"},{"key":"R27-51-20210309","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejon.2013.11.009","article-title":"European Oncology Nursing Society breakthrough cancer pain guidelines","volume":"18","author":"Wengstrom","year":"2014","journal-title":"Eur J Oncol Nurs"},{"key":"R29-51-20210309","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jjco\/hyn010","article-title":"Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial","volume":"38","author":"Narabayashi","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"R31-51-20210309","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00044011-200727040-00005","article-title":"Efficacy and tolerability of oxycodone hydrochloride controlled-release tablets in moderate to severe cancer pain","volume":"27","author":"Pan","year":"2007","journal-title":"Clin Drug Investig"},{"key":"R32-51-20210309","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-94-017-7537-3_9","article-title":"Advances in the treatment of neuropathic pain","volume":"904","author":"Xu","year":"2016","journal-title":"Adv Exp Med Biol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000003341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T16:23:27Z","timestamp":1655655807000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201604120-00051"}},"subtitle":["A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":29,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000003341","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}